CYTK · NASDAQ · STOCK
Cytokinetics (CYTK) Stock Analysis
$62.95
52W $54.30 – $88.31
50/100
$7.83B
-8.7
0.36
Is CYTK Bullish or Bearish?
Mixed.
Innellis AI committee rates Cytokinetics (CYTK) Watch with a composite score of 50/100
, based on 6 analysts with 33% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +9.66 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -10.34 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. News Analyst sees a compelling case — news sentiment is positive (+0.33 across 6 articles, 14d). Value Analyst remains cautious — price-to-book of 15.7x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
- News sentiment is positive (+0.33 across 6 articles, 14d) — News
Bear Case
- Price-to-book of 15.7x prices in significant intangible value — Value
- ROE of only -131.2% -- cheap may mean cheap for a reason — Value
- Revenue declining -21.1% YoY -- this is not a growth story right now — Growth
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 18.4% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
50/100
Agreement
33%
Analysts
6
Conviction
Contested
Sector Rank
Top 92%
of 192 Healthcare peers
Value Analyst
bearish
30
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− Price-to-book of 15.7x prices in significant intangible value
Growth Analyst
neutral
50
/ 100 · Moderate confidence
Moderate growth -- present but not remarkable
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
− Revenue declining -21.1% YoY -- this is not a growth story right now
Technical Analyst
neutral
54
/ 100 · High confidence
Mixed or range-bound price action
+ Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement
− MACD histogram negative -- bearish momentum
Risk Analyst
bearish
35
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Bollinger bandwidth of 18.4% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
68
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.33 across 6 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 48.6 to 50.3.
- New bearish signals: 1 appeared.
- Bullish support removed: 1 signal(s) disappeared.
- New bullish signals: 1 appeared.
- Bearish pressure eased: 2 signal(s) disappeared.
Analyst-level changes:
- News Analyst: +1 bullish signal(s).
- Risk Analyst: +1 bearish signal(s).
- Technical Analyst: score 46->54 (+8).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
36.1
Neutral
MACD Histogram
-0.131
Bearish Momentum
Trend Direction
Sideways
Weekly: Sideways
Market Structure
Mixed
Support
$61.67
Resistance
$68.68
Bollinger %B
0.25
Inside Bands
Price vs Moving Averages
EMA 9
$63.51
Below
EMA 21
$66.16
Below
EMA 50
$70.25
Below
EMA 200
$69.07
Below
Fundamental Analysis
Valuation
100
Growth
45
Profitability
50
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-8.7×
P/B Ratio
-47.90×
PEG Ratio
0.26
Dividend Yield
0.00%
52W High
$88.31
52W Low
$54.30
Quality & Growth
ROE
11900.0%
ROA
-5510.2%
Gross Margin
8497.3%
Operating Margin
—
Revenue Growth YoY
—
Debt / Equity
-7.32
AI Fundamental Assessment
P/E ratio of -8.7 (inexpensive relative to a 15-40x range); Price-to-book of -47.9x; PEG ratio of 0.3 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 119.0%; Return on assets of -55.1%; Net margin of -1259.9%; Gross margin of 85.0%; Current ratio of 6.66 (healthy short-term liquidity); Debt-to-equity of -7.32; Free cash flow per share is negative (-4.40); Most recent quarter beat estimates by 10.4%; 2 consecutive earnings beats; EPS growth accelerating (-11.3% -> +10.2% QoQ); Average YoY EPS growth of -33.9%; Analyst estimates falling over recent quarters
Get the Full CYTK Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →